Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice

• Main Authors: Hori Yuko (Author), Hamano Hiroki (Author), Yoshinaga Koji (Author), Kobayashi Nobuyoshi (Author), Seto Koichi (Author), Kato Hiroki (Author), Orikawa Yuki (Author), Meyer Tim (Author), Takei Mineo (Author)
• Format: Book
• Published: SAGE Publishing, 2010-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

<p>Abstract</p> <p>Background</p> <p>Z-360 is an orally active cholecystokinin-2 (CCK2)/gastrin receptor antagonist currently under development as a therapeutic drug for pancreatic cancer. It was previously reported that Z-360 treatment in combination with gemcitabine p...